Thiogenesis Therapeutics Corp(TTI-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.560
Day High0.590
Open:0.590
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors
Newsfile
Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
Newsfile
Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares
Newsfile
Thiogenesis Announces Non-Brokered Private Placement
Newsfile
Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
Newsfile
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update
Newsfile
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
Newsfile
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
Newsfile
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
GlobeNewswire
Thiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11th
Newsfile
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
Newsfile
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
Newsfile
Thiogenesis Announces Extension to Investor Relations Agreement
Newsfile
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update
Newsfile
Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares
Newsfile
Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares
Newsfile
Thiogenesis Upsizes Fully Subscribed Non-Brokered Private Placement of Common Shares
Newsfile
Thiogenesis Announces Non-Brokered Private Placement of Common Shares

Profile

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic drug product candidates, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the company's flagship drug product candidate, was developed to address the obstacles facing existing thiol-based drugs, their short half-live and side effects.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.